Detalhe da pesquisa
1.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
Cardiovasc Diabetol
; 23(1): 104, 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38504284
2.
Practical strategies to manage obesity in type 2 diabetes.
Diabetes Obes Metab
; 26(6): 2029-2045, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38514387
3.
Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease.
Cardiovasc Diabetol
; 22(1): 344, 2023 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38093293
4.
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
Cardiovasc Diabetol
; 22(1): 59, 2023 03 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36927451
5.
Glucagon in type 2 diabetes: Friend or foe?
Diabetes Metab Res Rev
; 39(3): e3609, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36637256
6.
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta-analysis.
Diabetes Obes Metab
; 25(5): 1301-1310, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36661362
7.
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Diabetes Obes Metab
; 25(3): 656-663, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36309941
8.
Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.
Diabetes Obes Metab
; 25(6): 1658-1667, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36789682
9.
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.
Diabetes Obes Metab
; 25(9): 2535-2544, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37254688
10.
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
Diabetes Obes Metab
; 25(9): 2553-2560, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37246796
11.
New insights into the treatment of obesity.
Diabetes Obes Metab
; 25(8): 2058-2072, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37055715
12.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Diabetes Obes Metab
; 25(12): 3453-3464, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37712754
13.
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Diabetes Obes Metab
; 25(12): 3465-3477, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37700627
14.
The p66Shc Redox Protein and the Emerging Complications of Diabetes.
Int J Mol Sci
; 25(1)2023 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38203279
15.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet
; 398(10300): 583-598, 2021 08 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34370970
16.
New strategies to improve clinical outcomes for diabetic kidney disease.
BMC Med
; 20(1): 337, 2022 10 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36210442
17.
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
Cardiovasc Diabetol
; 21(1): 162, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35999556
18.
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Cardiovasc Diabetol
; 21(1): 50, 2022 04 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35395808
19.
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
Diabetes Obes Metab
; 24(12): 2364-2372, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36053820
20.
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
Diabetes Obes Metab
; 24(12): 2391-2399, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36054624